Next Article in Journal
pMPES: A Modular Peptide Expression System for the Delivery of Antimicrobial Peptides to the Site of Gastrointestinal Infections Using Probiotics
Next Article in Special Issue
Methods of Synthesis, Properties and Biomedical Applications of CuO Nanoparticles
Previous Article in Journal
Lactoferrin from Milk: Nutraceutical and Pharmacological Properties
Previous Article in Special Issue
Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting—Ideal Versus Reality
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2016, 9(4), 62; doi:10.3390/ph9040062

Nanosized Drug Delivery Systems in Gastrointestinal Targeting: Interactions with Microbiota

1
Aberdeen, Scotland AB15 5LZ, UK
2
Department of Microbiology and Immunology, Faculty of Biology, University of Bucharest, Bucharest 77206, Romania
3
Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, Bucharest 011061, Romania
*
Author to whom correspondence should be addressed.
Academic Editor: Jean Jacques Vanden Eynde
Received: 24 August 2016 / Revised: 23 September 2016 / Accepted: 26 September 2016 / Published: 29 September 2016
(This article belongs to the Special Issue Nanobiotechnology in Medicinal Chemistry)
View Full-Text   |   Download PDF [476 KB, uploaded 29 September 2016]   |  

Abstract

The new age of nanotechnology has signaled a stream of entrepreneurial possibilities in various areas, form industry to medicine. Drug delivery has benefited the most by introducing nanostructured systems in the transport and controlled release of therapeutic molecules at targeted sites associated with a particular disease. As many nanosized particles reach the gastrointestinal tract by various means, their interactions with the molecular components of this highly active niche are intensively investigated. The well-characterized antimicrobial activities of numerous nanoparticles are currently being considered as a reliable and efficient alternative to the eminent world crisis in antimicrobial drug discovery. The interactions of nanosystems present in the gastrointestinal route with host microbiota is unavoidable; hence, a major research initiative is needed to explore the mechanisms and effects of these nanomaterials on microbiota and the impact that microbiota may have in the outcome of therapies entailing drug delivery nanosystems through the gastrointestinal route. These coordinated studies will provide novel techniques to replace or act synergistically with current technologies and help develop new treatments for major diseases via the discovery of unique antimicrobial molecules. View Full-Text
Keywords: antimicrobial; nanotechnology; pathogen; infection; gastrointestinal delivery; microbiota antimicrobial; nanotechnology; pathogen; infection; gastrointestinal delivery; microbiota
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Karavolos, M.; Holban, A. Nanosized Drug Delivery Systems in Gastrointestinal Targeting: Interactions with Microbiota. Pharmaceuticals 2016, 9, 62.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top